Marshall Wace, LLP Belite Bio, Inc Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Belite Bio, Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 5,865 shares of BLTE stock, worth $370,609. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,865
Previous 8,486
30.89%
Holding current value
$370,609
Previous $397,000
6.8%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BLTE
# of Institutions
22Shares Held
280KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY168KShares$10.6 Million0.15% of portfolio
-
State Street Corp Boston, MA20KShares$1.26 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC18.3KShares$1.16 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY14.6KShares$924,8480.0% of portfolio
-
Ubs Group Ag12.2KShares$771,3600.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.57B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...